Velikova T, Gulinac M. Novel insights into autophagy in gastrointestinal pathologies, mechanisms in metabolic dysfunction-associated fatty liver disease and acute liver failure. World J Gastroenterol 2024; 30(27): 3273-3277 [PMID: 39086749 DOI: 10.3748/wjg.v30.i27.3273]
Corresponding Author of This Article
Milena Gulinac, MD, PhD, Academic Research, Department of General and Clinical Pathology, Medical University of Plovdiv, 15A Vassil Aprilov Blvd, Plovdiv 4002, Bulgaria. mgulinac@hotmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jul 21, 2024; 30(27): 3273-3277 Published online Jul 21, 2024. doi: 10.3748/wjg.v30.i27.3273
Novel insights into autophagy in gastrointestinal pathologies, mechanisms in metabolic dysfunction-associated fatty liver disease and acute liver failure
Tsvetelina Velikova, Milena Gulinac
Tsvetelina Velikova, Milena Gulinac, Medical Faculty, Sofia University St Kliment Ohridski, Sofia 1407, Bulgaria
Milena Gulinac, Department of General and Clinical Pathology, Medical University of Plovdiv, Plovdiv 4002, Bulgaria
Author contributions: Velikova T and Gulinac M wrote the paper; Velikova T revised the paper; All authors approved the final version of the manuscript before submission.
Supported bythe European Union-NextGenerationEU, through The National Recovery and Resilience Plan of The Republic of Bulgaria, No. BG-RRP-2.004-0008.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Milena Gulinac, MD, PhD, Academic Research, Department of General and Clinical Pathology, Medical University of Plovdiv, 15A Vassil Aprilov Blvd, Plovdiv 4002, Bulgaria. mgulinac@hotmail.com
Received: March 21, 2024 Revised: May 26, 2024 Accepted: June 24, 2024 Published online: July 21, 2024 Processing time: 111 Days and 18.3 Hours
Abstract
In this editorial, we comment on three articles published in a recent issue of World Journal of Gastroenterology. There is a pressing need for new research on autophagy's role in gastrointestinal (GI) disorders, and also novel insights into some liver conditions, such as metabolic dysfunction-associated fatty liver disease (MAFLD) and acute liver failure (ALF). Despite advancements, understanding autophagy's intricate mechanisms and implications in these diseases remains incomplete. Moreover, MAFLD's pathogenesis, encompassing hepatic steatosis and metabolic dysregulation, require further elucidation. Similarly, the mechanisms underlying ALF, a severe hepatic dysfunction, are poorly understood. Innovative studies exploring the interplay between autophagy and GI disorders, as well as defined mechanisms of MAFLD and ALF, are crucial for identifying therapeutic targets and enhancing diagnostic and treatment strategies to mitigate the global burden of these diseases.
Core Tip: Exploration of autophagy's role in gastrointestinal (GI) disorders, as well as metabolic dysfunction-associated fatty liver disease (MAFLD) and acute liver failure (ALF), is imperative for advancing diagnostic and treatment strategies in gastroenterological diseases. Despite advancements, understanding autophagy's intricate mechanisms in these conditions remains incomplete. Further research into MAFLD's diagnostic markers and treatment modalities, considering its hepatic steatosis and metabolic dysregulation, is crucial. Elucidating diagnostic and therapeutic approaches for ALF, a severe hepatic dysfunction, is essential. Investigating autophagy's implications in diagnosing and treating GI disorders, MAFLD, and ALF is pivotal for improving patient outcomes.
